Drug Profile
Amlodipine/rosuvastatin - Yuhan
Alternative Names: Rosuampin; YH-1701; YHP-1701; YHR-1703/YHR-1704; YHR-1704/YHR-1703Latest Information Update: 04 Feb 2021
Price :
$50
*
At a glance
- Originator Yuhan
- Class Amines; Antihyperlipidaemics; Antihypertensives; Carboxylic acids; Chlorobenzenes; Dihydropyridines; Esters; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
Most Recent Events
- 21 Dec 2020 Phase III development is ongoing South Korea
- 30 Sep 2020 Discontinued - Phase-III for Hyperlipidaemia in South Korea (PO) (Yuhan pipeline, September 2020)
- 30 Sep 2020 Discontinued - Phase-III for Hypertension in South Korea (PO) (Yuhan pipeline, September 2020)